Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Uhl

Showing results (441-450 of 526) with videos related to

Pageof 53
Sort By:
Journal of Pharmacological Sciences|January 23, 2004
Lack of mu-opioid receptor-mediated G-protein activation in the spinal cord of mice lacking Exon 1 or Exons 2 and 3 of the MOR-1 geneHirokazu Mizoguchi, Hsiang-En Wu, Minoru Narita, et al.
Expert Opinion on Pharmacotherapy|February 27, 2009
Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: a randomised controlled trialO Löwenstein, P Leyendecker, M Hopp, et al.
European Journal of Medicinal Chemistry|July 13, 2005
Structure-activity relationship of trihexyphenidyl analogs with respect to the dopamine transporter in the on going search for a cocaine inhibitorD E Dar, M Thiruvazhi, P Abraham, et al.
Plos One|June 3, 2017
Molecular epidemiology of Staphylococcus aureus bacteremia in a single large Minnesota medical center in 2015 as assessed using MLST, core genome MLST and spa typingKyung-Hwa Park, Kerryl E Greenwood-Quaintance, James R Uhl, et al.
Methods in Molecular Medicine|March 2, 2006
Molecular neurobiological methods in marijuana-cannabinoid researchGeorge R Uhl, Hiroki Ishiguro, Emmanuel S Onaivi, et al.
Journal of Studies on Alcohol and Drugs|November 21, 2024
Polygenic Risk for Substance Use Disorders as Predictors of Substance Use Initiation Among African American YouthDavid W Sosnowski, Jill A Rabinowitz, Kenneth A Feder, et al.
Behavioural Pharmacology|September 29, 2025
Pretreatment with LY2090314, a potent glycogen synthase kinase-3 inhibitor, suppresses methamphetamine-induced stereotyped behavior but not hyperlocomotion in miceKentaro Matsuda, Nobue Kitanaka, Frank Scott Hall, et al.
Archives of General Psychiatry|September 1, 1992
Genetic vulnerability to drug abuse. The D2 dopamine receptor Taq I B1 restriction fragment length polymorphism appears more frequently in polysubstance abusersS S Smith, B F O'Hara, A M Persico, et al.
Psychopharmacology|March 23, 2007
Methamphetamine-induced locomotor activity and sensitization in dopamine transporter and vesicular monoamine transporter 2 double mutant miceSetsu Fukushima, Haowei Shen, Harumi Hata, et al.
Biochemical and Biophysical Research Communications|February 16, 2013
Exclusive expression of VMAT2 in noradrenergic neurons increases viability of homozygous VMAT2 knockout miceArihisa Ohara, Yoshiyuki Kasahara, Hideko Yamamoto, et al.
Pageof 53

Showing results (441-450 of 526) with videos related to

Sort By:
Pageof 53
Journal of Pharmacological Sciences|January 23, 2004
Lack of mu-opioid receptor-mediated G-protein activation in the spinal cord of mice lacking Exon 1 or Exons 2 and 3 of the MOR-1 geneHirokazu Mizoguchi, Hsiang-En Wu, Minoru Narita, et al.
Expert Opinion on Pharmacotherapy|February 27, 2009
Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: a randomised controlled trialO Löwenstein, P Leyendecker, M Hopp, et al.
European Journal of Medicinal Chemistry|July 13, 2005
Structure-activity relationship of trihexyphenidyl analogs with respect to the dopamine transporter in the on going search for a cocaine inhibitorD E Dar, M Thiruvazhi, P Abraham, et al.
Plos One|June 3, 2017
Molecular epidemiology of Staphylococcus aureus bacteremia in a single large Minnesota medical center in 2015 as assessed using MLST, core genome MLST and spa typingKyung-Hwa Park, Kerryl E Greenwood-Quaintance, James R Uhl, et al.
Methods in Molecular Medicine|March 2, 2006
Molecular neurobiological methods in marijuana-cannabinoid researchGeorge R Uhl, Hiroki Ishiguro, Emmanuel S Onaivi, et al.
Journal of Studies on Alcohol and Drugs|November 21, 2024
Polygenic Risk for Substance Use Disorders as Predictors of Substance Use Initiation Among African American YouthDavid W Sosnowski, Jill A Rabinowitz, Kenneth A Feder, et al.
Behavioural Pharmacology|September 29, 2025
Pretreatment with LY2090314, a potent glycogen synthase kinase-3 inhibitor, suppresses methamphetamine-induced stereotyped behavior but not hyperlocomotion in miceKentaro Matsuda, Nobue Kitanaka, Frank Scott Hall, et al.
Archives of General Psychiatry|September 1, 1992
Genetic vulnerability to drug abuse. The D2 dopamine receptor Taq I B1 restriction fragment length polymorphism appears more frequently in polysubstance abusersS S Smith, B F O'Hara, A M Persico, et al.
Psychopharmacology|March 23, 2007
Methamphetamine-induced locomotor activity and sensitization in dopamine transporter and vesicular monoamine transporter 2 double mutant miceSetsu Fukushima, Haowei Shen, Harumi Hata, et al.
Biochemical and Biophysical Research Communications|February 16, 2013
Exclusive expression of VMAT2 in noradrenergic neurons increases viability of homozygous VMAT2 knockout miceArihisa Ohara, Yoshiyuki Kasahara, Hideko Yamamoto, et al.
Pageof 53